![](/img/cover-not-exists.png)
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)
Geller, James I., Perentesis, John P., Liu, Xiaowei, Minard, Charles G., Kudgus, Rachel A., Reid, Joel M., Fox, Elizabeth, Blaney, Susan M., Weigel, Brenda J.Language:
english
Journal:
Pediatric Blood & Cancer
DOI:
10.1002/pbc.26565
Date:
April, 2017
File:
PDF, 321 KB
english, 2017